Factors associated with early quality-of-life response to palliative care during hematopoietic cell transplantation
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
ABSTRACT: Limited data exist on factors associated with early quality-of-life (QOL) response to palliative care (PC) in patients undergoing hematopoietic cell transplantation (HCT). We conducted a secondary analysis from 2 randomized clinical trials of PC vs usual care in adults with hematologic malignancies undergoing HCT. We measured patient-reported QOL, physical and psychological symptoms, and coping (categorized as approach-oriented and avoidant) at the time of HCT admission and 2 weeks, 3 months, and 6 months after HCT. PC clinicians completed weekly surveys documenting PC domains addressed. We defined early QOL response to PC as the change in Functional Assessment of Cancer Therapy-Bone Marrow Transplant total score from HCT admission to week 2, using the median split to define "high" responders. A total of 252 participants were included in analyses. The median change in QOL from HCT admission to week 2 was -10.7 (range, -77.0 to +52.0). Minoritized race (odds ratio [OR], 3.2; P < .001), lower baseline QOL (OR, 0.97; P < .001), and higher physical (OR, 1.02; P = .004) and posttraumatic stress disorder symptoms (OR, 1.04; P = .008) were associated with being a high PC responder. High PC responders reported greater use of approach-oriented coping at week 2 (Δ = 2.5; P = .002) and 3 months (Δ = 1.7; P = .04) and 6 months after HCT (Δ = 2.6; P = .003). Based on PC clinician surveys during HCT, high responders' PC visits focused on coping, illness/HCT education, and symptom education, whereas low responders' visits focused on symptom management. These findings provide insights into factors associated with early QOL response to PC in HCT and help identify those most likely to benefit in real-world practice. These trials were registered at www.ClinicalTrials.gov as #NCT02207322 and #NCT03641378.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Factors associated with early quality-of-life response to palliative care during hematopoietic cell transplantation
- Date Crossref
- 23/04/2025
- Éditeur
- American Society of Hematology
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Harvard University pays non établi dans la noticeUniversité ou école supérieure
-
Massachusetts General Hospital Department of Medicine pays non établi dans la noticeÉtablissement de santé
-
Brigham and Women's Hospital pays non établi dans la noticeÉtablissement de santé
-
Dana-Farber Cancer Institute pays non établi dans la noticeStructure de recherche
-
MGH Institute of Health Professions pays non établi dans la noticeÉtablissement de santé
-
University of Washington pays non établi dans la noticeUniversité ou école supérieure
-
Oregon Health & Science University pays non établi dans la noticeUniversité ou école supérieure
-
Duke University Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Fred Hutch Cancer Center pays non établi dans la noticeOrganisation à but non lucratif
-
Boston pays non établi dans la noticeInstitution
-
Oregon Health and Science University pays non établi dans la noticeUniversité ou école supérieure
-
Fred Hutchinson Cancer Center pays non établi dans la noticeInstitution
Harvard University, Department of Medicine — Massachusetts General Hospital et Brigham and Women's Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.